Pellow S, File S E
Behav Brain Res. 1987 Feb;23(2):159-66. doi: 10.1016/0166-4328(87)90052-0.
CL 218,872, tracazolate and tofisopam are compounds that are believed to act at the GABA-benzodiazepine (BDZ) receptor complex in the CNS and that have anxiolytic properties in animals or in man. Doses of each drug were selected to elevate, or to depress, exploratory head-dipping and locomotor activity in the holeboard in mice, and the development of tolerance to these effects was investigated. As previously found with benzodiazepines, tolerance did not develop to the stimulant effects of low doses of these compounds after 10 days pretreatment with either a low (stimulant) or a high (depressant) dose of the same compound. When animals were pretreated with a low (stimulant) dose, tolerance did not develop to the depressant effects of a high test dose. Tolerance was observed only to the depressant effects of a high dose of a drug, and only when animals were also pretreated with a high dose. The results are compared with those obtained with benzodiazepines, and the ability of current theories of tolerance to account for the results is discussed.
CL 218,872、曲卡唑酯和托非索泮是据信作用于中枢神经系统中γ-氨基丁酸-苯二氮䓬(BDZ)受体复合物且在动物或人体中具有抗焦虑特性的化合物。选择每种药物的剂量以提高或降低小鼠在洞板实验中的探究性头部下垂和运动活动,并研究对这些作用的耐受性发展情况。如先前对苯二氮䓬类药物的研究发现,用低剂量(兴奋型)或高剂量(抑制型)的同一种化合物预处理10天后,对这些化合物低剂量的兴奋作用不会产生耐受性。当动物用低剂量(兴奋型)预处理时,对高测试剂量的抑制作用不会产生耐受性。仅在高剂量药物的抑制作用方面观察到耐受性,且仅当动物也用高剂量预处理时才会出现。将结果与用苯二氮䓬类药物获得的结果进行比较,并讨论了当前耐受性理论解释这些结果的能力。